Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $59.02 which represents a decrease of $-0.80 or -1.34% from the prior close of $59.82. The stock opened at $59.82 and ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Developing skills, assisting with research projects and helping to develop technological innovations within the nuclear ...

Bristol Myers's stock (BMY) was up more than 11% in afternoon trading, while AbbVie shares (ABBV) were down more than 12%. In a statement, AbbVie said that its phase 2 trial investigating emraclidine ...